About Us
 
Don Hayden
Don Hayden
Chairman and CEO

Don Hayden brings broad pharmaceutical and biotech experience and insight to the WindMIL Board. Mr. Hayden had a highly successful 25-year career with the Bristol-Myers Squibb Company and continues to hold key roles at a number of entrepreneurial pharmaceutical and biotech companies. At Bristol-Myers Squibb, he served as president of Global Pharmaceuticals; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group and president of Oncology and Immunology. Since leaving Bristol-Myers Squibb in early 2006, he has served as Chairman of REGENXBIO, Insmed, Vitae Pharmaceuticals, and Gloucester Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals.